专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08703140B2 Inhibition of factor B, the alternative complement pathway and methods related thereto 有权
公开(公告)号：US08703140B2
公开(公告)日：2014-04-22
申请号：US11843617
申请日：2007-08-22
申请人： V. Michael Holers , Joshua M. Thurman , Christian Taube , Erwin W. Gelfand , Gary Gilkeson
发明人： V. Michael Holers , Joshua M. Thurman , Christian Taube , Erwin W. Gelfand , Gary Gilkeson
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/544 , C07K2317/34 , C07K2317/76 , C07K2319/30
摘要： Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

2. 发明申请

US20110229497A1 Modulating the Alternative Complement Pathway 有权
标题翻译：调制替代补充途径
公开(公告)号：US20110229497A1
公开(公告)日：2011-09-22
申请号：US13120125
申请日：2009-09-22
申请人： Joshua M. Thurman , V. Michael Holers
发明人： Joshua M. Thurman , V. Michael Holers
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K16/18 , A61K38/00 , A61K38/1709 , A61K38/177 , C07K14/4721 , C07K2317/54 , C07K2317/55 , C07K2319/70 , C12N9/88 , C12Y402/01002
摘要： Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
摘要翻译：本文提供了组合物，包括药物组合物和调节，即刺激或抑制替代补体途径的活性的方法，以及鉴定因子H结合蛋白的方法。

3. 发明授权

US09815890B2 Antibodies to the C3d fragment of complement component 3 有权
公开(公告)号：US09815890B2
公开(公告)日：2017-11-14
申请号：US13805522
申请日：2011-06-22
申请人： V. Michael Holers , Joshua M. Thurman , Liudmila Kulik , Stephen Tomlinson
发明人： V. Michael Holers , Joshua M. Thurman , Liudmila Kulik , Stephen Tomlinson
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , C07K14/47
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

4. 发明授权

US08840868B2 Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles 有权
标题翻译：使用CR2靶向纳米颗粒的非侵入性检测补体介导的炎症
公开(公告)号：US08840868B2
公开(公告)日：2014-09-23
申请号：US13148028
申请日：2010-02-04
申请人： Joshua M. Thurman , Natalie Serkova , Conrad Stoldt , Brian Larsen , V. Michael Holers
发明人： Joshua M. Thurman , Natalie Serkova , Conrad Stoldt , Brian Larsen , V. Michael Holers
IPC分类号： A61K49/00 , A61B5/055 , B82Y5/00 , A61K49/18 , A61K49/16
CPC分类号： A61K49/1812 , A61K49/16 , A61K49/1863 , A61K49/1866 , A61K49/1875 , A61K49/1887 , B82Y5/00
摘要： Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided.
摘要翻译：提供补体介导炎症的非侵入性成像方法。还提供了包括用于这些方法的CR靶向超小超顺磁性纳米颗粒或其聚集体的组合物。

5. 发明申请

US20130078245A1 ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3 审中-公开
标题翻译： C3d补丁组件的抗体3
公开(公告)号：US20130078245A1
公开(公告)日：2013-03-28
申请号：US13589079
申请日：2012-08-17
申请人： V. Michael Holers , Joshua M. Thurman , Liudmila Kulik
发明人： V. Michael Holers , Joshua M. Thurman , Liudmila Kulik
IPC分类号： C07K16/18 , C07K14/47
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
摘要翻译：本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向预防性或治疗剂可以与身体内的组织的局部区域相比，其可以以非靶向的系统方式与相同或相似的药物的给药相比，其可以更直接地将其作用发挥到预定的靶细胞或组织上，具有减少的相关系统效应。因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。

6. 发明授权

US08937046B2 Modulating the alternative complement pathway 有权
标题翻译：调节替代补体途径
公开(公告)号：US08937046B2
公开(公告)日：2015-01-20
申请号：US13120125
申请日：2009-09-22
申请人： Joshua M. Thurman , V. Michael Holers
发明人： Joshua M. Thurman , V. Michael Holers
IPC分类号： A61K38/16 , A61K38/17 , C07K14/47 , A61K38/00
CPC分类号： C07K16/18 , A61K38/00 , A61K38/1709 , A61K38/177 , C07K14/4721 , C07K2317/54 , C07K2317/55 , C07K2319/70 , C12N9/88 , C12Y402/01002
摘要： Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
摘要翻译：本文提供了组合物，包括药物组合物和调节，即刺激或抑制替代补体途径的活性的方法，以及鉴定因子H结合蛋白的方法。

7. 发明申请

US20130129728A1 ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3 有权
标题翻译： C3D补丁组件的抗体3
公开(公告)号：US20130129728A1
公开(公告)日：2013-05-23
申请号：US13805522
申请日：2011-06-22
申请人： V. Michael Holers , Joshua M. Thurman , Liudmila Kulik
发明人： V. Michael Holers , Joshua M. Thurman , Liudmila Kulik
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
摘要翻译：本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向诊断的方法和材料，预防和治疗剂可以与身体内组织的局部区域直接发挥作用，与预定的靶细胞或组织相比，以相对于或相似的药物以非靶向的系统方式施用相比，具有减少的相关系统效应。因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。

8. 发明申请

US20080221011A1 Targeting complement factor H for treatment of diseases 有权
标题翻译：靶向补体因子H用于治疗疾病
公开(公告)号：US20080221011A1
公开(公告)日：2008-09-11
申请号：US11821370
申请日：2007-06-21
申请人： Gary Gilkeson , Stephen Tomlinson , V. Michael Holers , Baerbel Rohrer
发明人： Gary Gilkeson , Stephen Tomlinson , V. Michael Holers , Baerbel Rohrer
IPC分类号： A61K38/02 , C07K2/00 , C07K19/00 , C07H21/04 , C12N15/63 , C12N5/06
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
摘要翻译：本发明提供包含CR2部分的CR2-FH分子，其包含CR2蛋白或其片段和包含因子H蛋白或其片段的FH部分和包含CR2-FH分子的药物组合物。还提供了使用组合物治疗涉及替代补体途径的疾病的方法，例如年龄相关性黄斑变性，类风湿性关节炎和缺血再灌注。

9. 发明授权

US08569225B2 Targeting complement factor H for treatment of diseases 有权
公开(公告)号：US08569225B2
公开(公告)日：2013-10-29
申请号：US12782526
申请日：2010-05-18
申请人： Gary Gilkeson , Stephen Tomlinson , V. Michael Holers , Baerbel Rohrer
发明人： Gary Gilkeson , Stephen Tomlinson , V. Michael Holers , Baerbel Rohrer
IPC分类号： C07K14/00 , C12N15/00
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

10. 发明授权

US07759304B2 Targeting complement factor H for treatment of diseases 有权
标题翻译：靶向补体因子H用于治疗疾病
公开(公告)号：US07759304B2
公开(公告)日：2010-07-20
申请号：US11821370
申请日：2007-06-21
申请人： Gary Gilkeson , Stephen Tomlinson , V. Michael Holers , Baerbel Rohrer
发明人： Gary Gilkeson , Stephen Tomlinson , V. Michael Holers , Baerbel Rohrer
IPC分类号： C07K14/00
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
摘要翻译：本发明提供包含CR2部分的CR2-FH分子，其包含CR2蛋白或其片段和包含因子H蛋白或其片段的FH部分和包含CR2-FH分子的药物组合物。还提供了使用组合物治疗涉及替代补体途径的疾病的方法，例如年龄相关性黄斑变性，类风湿性关节炎和缺血再灌注。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式